



## Índice de intervenções por tema

### B. IMAGING -> 03. IMAGING -> 03.1 ECHOCARDIOGRAPHY

- CO 24 PEAK STRAIN DISPERSION: A NEW PROMISING PROGNOSTIC PREDICTOR EARLY AFTER STEMI
- CO 27 MYOCARDIAL WORK IMPROVEMENT AFTER SACUBITRIL-VALSARTAN: A NEW PARAMETER FOR A NEW TREATMENT
- CO 61 DISPROPORTIONATE FUNCTIONAL MITRAL REGURGITATION: CLINICAL VALIDATION OF A NEW CONCEPTUAL FRAMEWORK
- P 13 DELTA GLOBAL LONGITUDINAL STRAIN PREDICTS MAJOR CARDIOVASCULAR EVENTS AFTER A FIRST ACUTE CORONARY SYNDROME
- P 15 A NEW MODEL FOR ACCURATE NON-INVASIVE PREDICTION OF TRANSPULMONARY PEAK-TO-PEAK GRADIENTS
- P 16 LEFT VENTRICULAR REMODELLING PATTERNS AFTER MITRACLIP IMPLANTATION: DO ISCHEMIC PATIENTS HAVE THE SAME BENEFIT?
- P 17 PREDICTORS AND PROGNOSTIC IMPACT OF EARLY EF RECOVERY IN PATIENTS WITH AS AND REDUCED EF AFTER TAVI
- P 157 RIGHT VENTRICLE DEFORMATION IMAGING USE IN BRUGADA SYNDROME PATIENTS: A USEFUL TOOL?
- P 159 HOW TO PREDICT ATRIAL FIBRILLATION IN MITRAL VALVE PROLAPSE PATIENTS?
- P 160 LEFT ATRIAL STRAIN: HAVE WE FOUND THE MISSING PIECE OF THE PUZZLE?
- P 161 RIGHT VENTRICULAR OUTFLOW TRACT PREMATURE VENTRICULAR CONTRACTIONS AND RIGHT VENTRICULAR FUNCTION ASSESSED BY TWO-DIMENSIONAL SPECKLE TRACKING ECHOCARDIOGRAPHY
- P 228 VALVE INDICES IMPROVEMENT IS NOT FOLLOWED BY THE LONGITUDINAL STRAIN AFTER AORTIC VALVE SUBSTITUTION
- P 232 MITRAL VALVE PROLAPSE - IS IT A DEFECT OR OFTEN JUST A FEATURE?
- P 233 ECHOCARDIOGRAPHY RED FLAGS FOR CARDIAC AMYLOIDOSIS IN PATIENTS WITH SEVERE AORTIC STENOSIS
- P 300 STRESS ECHOCARDIOGRAPHY IN MULTIVESSEL CORONARY ARTERY DISEASE - 12 MONTHS FOLLOW UP
- P 302 PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY - IS THIS A SAFE EXAM TO PERFORM? DATA FROM A 6-YEAR SINGLE CENTRE EXPERIENCE
- P 342 MYOCARDIAL WORK INDEXES IN ADULT PATIENTS WITH REPAIRED AORTIC COARTATION
- P 345 MYOCARDIAL WORK BY ECHOCARDIOGRAPHY IN PATIENTS WITH BICUSPID AORTIC VALVES

### B. IMAGING -> 03. IMAGING -> 03.2 COMPUTED TOMOGRAPHY

- CO 14 OPTIMIZING DIAGNOSIS OF OBSTRUCTIVE CORONARY ARTERY DISEASE BY CT ANGIOGRAPHY: RCT'S FINAL RESULTS
- CO 26 PRE-TEST PROBABILITY OF OBSTRUCTIVE CAD IN THE NEW GUIDELINES: TOO MUCH, TOO LITTLE OR JUST ENOUGH?
- P 14 DOWNSTREAM TESTING AFTER AN HALTED CORONARY CT ANGIOGRAPHY DUE TO HIGH CORONARY ARTERY CALCIUM SCORE
- P 84 DOES CORONARY CALCIUM SCORING ADDS VALUE TO CARDIOVASCULAR RISK PREDICTION IN ASYMPTOMATIC PEOPLE?
- P 85 UNVEILING CORONARY INFLAMMATION BY PERIVASCULAR FAT ANGIO-CT: A PROPENSITY-MATCHED SCORE ANALYSIS
- P 86 PREVALENCE OF LAA THROMBUS IN PATIENTS UNDERGOING PERCUTANEOUS ABLATION OF ATRIAL FIBRILLATION
- P 87 EPICARDIAL ADIPOSE TISSUE AND CALCIFIC AORTIC STENOSIS - UNVEILING A LONG-DISTANCE RELATIONSHIP

- P 88 DIAGNOSTIC YIELD OF CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY IN SYMPTOMATIC ELDERLY PATIENTS
- P 89 DOSE ATUAL DE RADIAÇÃO EM TC CORONÁRIA - FATORES CONTRIBUTIVOS E RELAÇÃO COM QUALIDADE DE IMAGEM
- P 303 CORONARY ARTERY CALCIUM ASSOCIATED WITH ADVERSE EVENTS IN PATIENTS WITH NON-OBSTRUCTIVE CORONARY HEART DISEASE IN THE SCOT-HEART STUDY

## **B. IMAGING -> 03. IMAGING -> 03.3 CARDIAC MAGNETIC RESONANCE**

- CO 25 AXIAL MUSCLE SIZE QUANTIFICATION BY CARDIAC MRI AS A STRONG PREDICTOR OF MAJOR EVENTS IN HF
- CO 29 MYOCARDIAL EDEMA IN FABRY DISEASE
- CO 39 MACHINE LEARNING WALL THICKNESS MEASUREMENT IN HYPERTROPHIC CARDIOMYOPATHY EXCEEDS PERFORMANCE OF WORLD EXPERTS
- P 156 DIAGNOSTIC POWER OF CARDIAC MAGNETIC RESONANCE IN UNEXPLAINED OR SUSPECTED ARRHYTHMIAS
- P 158 MYOCARDIAL FIBROSIS IS A PREDICTOR OF AF IN DILATED CARDIOMYOPATHY - ROLE OF CMR
- P 231 HYPERTROPHIC CARDIOMYOPATHY: CAN WE PREDICT DYSRHYTHMIC EVENTS?
- P 305 CARDIAC MAGNETIC RESONANCE IN MINOCA PATIENTS: SEARCHING FOR THE FINAL DIAGNOSIS

## **B. IMAGING -> 03. IMAGING -> 03.4 NUCLEAR IMAGING**

- P 301 ISOLATED APICAL PERFUSION DEFECT IN SPECT/CT SCANS - IS THERE ANY PROGNOSTIC VALUE?
- P 304 MYOCARDIAL PERFUSION SCINTIGRAPHY PRIOR TO KIDNEY TRANSPLANT: THE ROLE OF ATTENUATION CORRECTION WITH COMPUTED TOMOGRAPHY

## **B. IMAGING -> 03. IMAGING -> 03.5 HYBRID AND FUSION IMAGING**

- CO 28 CARDIAC MICROCALCIFICATION BURDEN: GLOBAL ASSESSEMENT IN HIGH CARDIOVASCULAR RISK PATIENTS

## **B. IMAGING -> 03. IMAGING -> 03.6 CROSS-MODALITY AND MULTI-MODALITY IMAGING TOPICS**

- CO 15 TEMPORAL TRENDS IN REFERRAL PATTERNS FOR INVASIVE CORONARY ANGIOGRAPHY - A MULTICENTER 10-YEAR ANALYSIS
- CO 60 CALCIUM SCORE OF THE AORTIC VALVE AS AN AID TO GRADE AORTIC STENOSIS SEVERITY
- P 229 MYOCARDIAL WORK: A NEW WAY TO PREDICT FIBROSIS IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS

## **C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.3 ARRHYTHMIAS, GENERAL - DIAGNOSTIC METHODS**

- P 18 NON-INVASIVE MAPPING: MINIMAL NUMBER OF LEADS NEEDED TO OBTAIN A GOOD SPATIAL RESOLUTION IS HIGHER FOR ATRIAL ARRHYTHMIAS
- P 20 MAPPING THE REPOLARIZATION NONINVASIVELY WITH THE EPICARDIAL AND ENDOCARDIAL MAPPING SYSTEM- A VALIDATION STUDY

## **C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.4 ARRHYTHMIAS, GENERAL - TREATMENT**

- P 19 A NOVEL SIMPLIFIED APPROACH TO RADIOFREQUENCY CATHETER ABLATION OF IDIOPATHIC RIGHT VENTRICULAR OUTFLOW TRACT PREMATURE VENTRICULAR CONTRACTIONS

## **C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.5 ARRHYTHMIAS, GENERAL - PREVENTION**

- P 23 SUPRAVENTRICULAR ECTOPIC ACTIVITY AS A PREDICTOR OF ATRIAL FIBRILLATION - WHAT WE DIDN'T SEE 10 YEARS AGO

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.7 ARRHYTHMIAS, GENERAL - OTHER**

- CO 5 A MACHINE-LEARNING ALGORITHM TO PREDICT ATRIAL FIBRILLATION RECURRENCE AFTER A PULMONARY VEIN ISOLATION PROCEDURE
- P 22 PERMANENT PACEMAKER IMPLANTATION AFTER TAVI - LONG-TERM DEPENDENCY OR RHYTHM RECOVERY?

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.1 ATRIAL FIBRILLATION - PATHOPHYSIOLOGY AND MECHANISMS**

- CO 1 RELATIONSHIP BETWEEN EPICARDIAL FAT AND LEFT ATRIUM FIBROSIS IN PATIENTS WITH ATRIAL FIBRILLATION
- P 25 EPICARDIAL ADIPOSE TISSUE AND ATRIAL FIBRILLATION: GUILTY AS CHARGED OR GUILTY BY ASSOCIATION?

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.2 ATRIAL FIBRILLATION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- P 21 ARRHYTHMIA-INDUCED CARDIOMYOPATHY: CHARACTERIZATION AND OUTCOMES OF PATIENTS WITH RHYTHM OR RATE CONTROL IN A POPULATION WITH COMPLETE SUSTAINED RECOVERY OF FUNCTION
- P 164 CATHETER ABLATION IN ATRIAL FIBRILLATION: COMORBIDITIES AND MORTALITY FROM HIGH-VOLUME CENTERS
- P 165 DE NOVO ATRIAL FIBRILLATION IN ACUTE CORONARY SYNDROMES
- P 167 DOES ATRIAL FIBRILLATION HAVE A LONG-TERM PROGNOSTIC IMPACT IN ICD PATIENTS?

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.3 ATRIAL FIBRILLATION - DIAGNOSTIC METHODS**

- P 162 RATIONALE AND DESIGN OF THE "SCREENING OF ATRIAL FIBRILLATION AMONG ELDERLY IN PRIMARY CARE WITH MYDIAGNOSTIK" (SAFEST) STUDY

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.4 ATRIAL FIBRILLATION - TREATMENT**

- CO 3 THE LONG STORY OF FIRE AND ICE: WHO IS THE WINNER?
- P 24 EPICARDIAL FAT VOLUME OUTPERFORMS CLASSIC CLINICAL SCORES FOR PREDICTING ATRIAL FIBRILLATION RELAPSE AFTER PULMONARY VEIN ISOLATION
- P 26 RANOLAZINE AS YOU HAVE NEVER SEEN IT BEFORE: AN ANTIARRHYTHMIC FOR ATRIAL FIBRILLATION
- P 27 PROTON PUMP INHIBITORS IN PATIENTS WITH ATRIAL FIBRILLATION AND NEW-ONSET ACUTE HEART FAILURE
- P 28 SURGICAL ABLATION OF ATRIAL FIBRILLATION AND LEFT APPENDAGE OCCLUSION BY A TOTALLY VIDEOTHORACOSCOPIC APPROACH- A PARADIGM SHIFT?
- P 29 ATRIAL FRIBILLATION, IS SURGICAL TREATMENT AN EFFICIENT OPTION?
- P 166 WHO'S TOO OLD FOR EPICARDIAL FAT VOLUME QUANTIFICATION?

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.9 ATRIAL FIBRILLATION - OTHER**

- P 163 EFFECT OF ATRIAL FIBRILLATION ON NT-PROBNP LEVELS IN PATIENTS WITHOUT HEART FAILURE

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.2 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- P 306 ATRIAL ELECTRICAL IMPAIRMENT AND ATRIAL FIBRILLATION AFTER AV NODAL REENTRANT TACHYCARDIA ABLATION

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.2 SYNCOPE AND BRADYCARDIA - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- CO 37 HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: PREDICTORS OF CONDUCTION DISEASE
- P 90 THE AGE FACTOR - DIFFERENCES IN SYNCOPE RECURRENCE AND MORTALITY AFTER THE 40'S
- P 91 IATROGENIC BRADYARRHYTHMIA: PREVIOUS CONDUCTION DISTURBANCES PREDICTED NEED FOR PERMANENT PACING
- P 95 RECURRENT SYNCOPE - WHICH PATIENT SHOULD WE FOLLOW MORE CLOSELY?

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.4 SYNCOPE AND BRADYCARDIA - TREATMENT**

- CO 4 ANATOMIC GUIDED ABLATION OF THE RIGHT GANGLIONATED PLEXUS IS ENOUGH FOR CARDIAC AUTONOMIC DENERVATION IN PATIENTS WITH SIGNIFICANT BRADYARRHYTHMIAS
- P 94 LONG-TERM RESULTS OF TILT TRAINING IN PATIENTS WITH RECURRENT REFLEX SYNCOPE: FOCUS ON QUALITY OF LIFE AND AUTONOMIC MODULATION

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.6 SYNCOPE AND BRADYCARDIA - CLINICAL**

- P 92 CAN WE RULE-OUT CARDIOGENIC SYNCOPE AT A FIRST GLANCE?

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.1 VENTRICULAR ARRHYTHMIAS AND SCD - PATHOPHYSIOLOGY AND MECHANISMS**

- P 238 OBSTRUCTIVE SLEEP APNEA AND NIGHTTIME OXYGEN DESATURATION IN NOCTURNAL VENTRICULAR ARRHYTHMIAS

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.2 VENTRICULAR ARRHYTHMIAS AND SCD - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- P 234 GENDER RELATED DIFFERENCES IN BRUGADA SYNDROME
- P 309 FAMILY SCREENING IN A PORTUGUESE SAMPLE OF BRUGADA SYNDROME PATIENTS

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.3 VENTRICULAR ARRHYTHMIAS AND SCD - DIAGNOSTIC METHODS**

- CO 6 ELECTROCARDIOGRAPHIC NON TYPE-1 BRUGADA PATTERN CRITERIA IN THE YOUNG SCD-SOS COHORT
- P 235 3D ARCHITECTURE AND ARRHYTHMOGENIC POTENTIAL OF PREVIOUS MYOCARDIAL INFARCTION SCARS
- P 311 EKG LOCALIZATION OF IDIOPATHIC PVC ORIGIN BEFORE ABLATION: COMPARISON OF DIFFERENT ALGORITHMS

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.4 VENTRICULAR ARRHYTHMIAS AND SCD - TREATMENT**

- CO 2 COMBINED ENDOCARDIAL AND EPICARDIAL VENTRICULAR TACHYCARDIA ABLATION FOR ISCHEMIC AND NONISCHEMIC DILATED CARDIOMYOPATHY
- P 236 NON-CONTACT MULTI-ELECTRODE BALLOON CATHETER MAPPING-GUIDED ABLATION OF VENTRICULAR ARRHYTHMIAS ORIGINATING FROM THE OUTFLOW TRACT
- P 237 LONG-TERM OUTCOME OF SUBSTRATE-BASED ABLATION IN PATIENTS WITH RECURRENT ICD THERAPY AND DILATED CARDIOMYOPATHY: EXPERIENCE WITH HIGH-DENSITY MAPPING

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.5 VENTRICULAR ARRHYTHMIAS AND SCD - PREVENTION**

- P 239 ROLE OF LATE-POTENTIALS IN SIGNAL-AVERAGED ECG IN PREDICTING FLECAINIDE PROVOCATIVE TEST IN BRUGADA PATTERN
- P 310 IDIOPATHIC HFREF. IS THERE ROOM LEFT FOR DEFIBRILLATORS?

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.1 ANTIBRADYCARDIA PACING**

- P 173 CLINIC AND ECHOCARDIOGRAPHIC PREDICTOR FACTORS TO INCREASE LEADLESS PACEMAKER PROCEDURE TIME
- P 241 PERMANENT PACEMAKER IMPLANTATION AFTER SURGICAL AORTIC VALVE REPLACEMENT: IMPACT IN MID-TERM SURVIVAL
- CO 58 LONG-TERM PERFORMANCE OF LEADLESS PACEMAKER: RESULTS FROM A MULTICENTRE REGISTRY

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.2 IMPLANTABLE CARIOVERTER / DEFIBRILLATOR**

- P 172 LONG-TERM FOLLOW-UP IN PRIMARY AND SECONDARY PREVENTION ICD PATIENTS IN A MODERN COHORT
- P 240 PROGRAMMING TACHYCARDIA ZONES TO REDUCE AVOIDABLE DEFIBRILLATOR SHOCKS

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.3 CARDIAC RESYNCHRONIZATION THERAPY**

- CO 55 A MODIFIED SNARE TECHNIQUE IMPROVES LEFT VENTRICULAR LEAD IMPLANT SUCCESS AND RESPONSE RATE TO CARDIAC RESYNCHRONIZATION THERAPY
- CO 56 MULTIPOINT PACING IN CARDIAC RESYNCHRONIZATION THERAPY - HOW TO IMPROVE REMODELING CRITERIA AND ITS IMPACT IN QUALITY OF LIFE
- CO 57 HIS BUNDLE PACING AS AN ALTERNATIVE TO CARDIAC RESYNCHRONIZATION: A SINGLE CENTER EXPERIENCE
- CO 59 THE GENDER GAP IN CARDIAC RESYNCHRONISATION THERAPY
- P 96 CLINICAL RISK FACTORS FOR THE PREDICTION OF ACUTE KIDNEY INJURY POST CARDIAC RESYNCHRONIZATION THERAPY
- P 97 LONG TERM CLINICAL OUTCOMES AFTER CARDIAC RESYNCHRONIZATION THERAPY IMPLANTATION IN ELDERLY PATIENTS
- P 100 TRANSVENOUS LEAD VERSUS EPICARDIAL LEAD: IMPACT OF THE DIFFERENT APPROACH IN CARDIAC RESYNCHRONIZATION THERAPY
- P 168 CRT IMPLANTATION IN PATIENTS WITH BORDERLINE CRITERIA - IS IT WORTH IT?
- P 170 INITIAL EXPERIENCE WITH A NEW QUADRIPOLE ACTIVE FIXATION LEFT VENTRICULAR LEAD FOR CARDIAC RESYNCHRONIZATION THERAPY
- P 171 CARDIAC RESYNCHRONIZATION THERAPY: LEFT OR NON-LEFT BUNDLE BRANCH BLOCK? THAT IS THE QUESTION
- P 242 COMPARISON OF DE NOVO AND UPGRADE TO RESYNCHRONIZATION THERAPY: A PROPENSITY-SCORE MATCHED ANALYSIS
- P 243 WHEN TO IMPLANT CRT-P OR CRT-D IN THE ELDERLY?
- P 244 ATRIAL FIBRILLATION AND CARDIAC RESYNCHRONIZATION THERAPY - IS THIS COMBINATION TRULY BAD?
- P 245 WOMEN AS CANDIDATES FOR CRT - ARE THEY LESS BUT BETTER?

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.4 HOME AND REMOTE PATIENT MONITORING**

- P 99 REMOTE MONITORING ALERTS IN HEART FAILURE PATIENTS: WHICH PARAMETERS MATTER MOST?

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.5 DEVICE COMPLICATIONS AND LEAD EXTRACTION**

- CO 54 LEAD REMOVAL, A SAFE PROCEDURE IN A REFERRAL CENTER
- P 98 POCKET HEMATOMA IN PATIENTS WITH CARDIAC DEVICES: PREVALENCE, RISK FACTORS AND OUTCOME PREDICTORS
- P 101 NATURAL HISTORY OF RESYNCHRONIZED PATIENTS: EXPERIENCE OF A SINGLE CENTRE
- P 169 LEAD EXTRACTION WITH THE "PISA TECHNIQUE" - EXPERIENCE OF A PORTUGUESE TERTIARY CARE CENTER

### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.1 CHRONIC HEART FAILURE - PATHOPHYSIOLOGY AND MECHANISMS**

- CO 42 ANTIARRHYTHMIC EFFECT OF SACUBITRIL-VALSARTAN: CAUSE OR CONSEQUENCE OF CLINICAL IMPROVEMENT?
- P 83 HEART FAILURE WITH MID RANGE EJECTION FRACTION IN REAL LIFE HEART FAILURE POPULATION: A TRUE DIFFERENT CLASS?

### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.2 CHRONIC HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- CO 43 LUNG WATER QUANTIFICATION BY CARDIAC MAGNETIC RESONANCE IMAGING: A NOVEL PROGNOSTIC TOOL IN HF
- CO 44 CLINICAL OUTCOMES IN HFREF AND GOOD FUNCTIONAL CAPACITY: THE DECEPTION OF STABILITY
  - P 1 PROGNOSTIC VALUE OF THE CARDIORESPIRATORY OPTIMAL POINT DURING SUBMAXIMAL EXERCISE TESTING
  - P 2 A NEW CARDIOPULMONARY EXERCISE TESTING SCORE FOR PREDICTING HEART FAILURE EVENTS
  - P 3 SLEEP APNEA IN HEART FAILURE: IN SEARCH OF A BETTER PROGNOSIS PREDICTOR
  - P 6 NEUTROPHIL-TO-LYMPHOCYTE RATIO IN ACUTE DECOMPENSATED HEART FAILURE: CAN IT PREDICT THE PROGNOSIS?
  - P 72 RISK STRATIFICATION IN HF WITH MID-RANGE LVEF: THE ROLE OF CARDIOPULMONARY EXERCISE TESTING
  - P 73 CARDIOPULMONARY EXERCISE TESTING IN FEMALE HEART FAILURE PATIENTS: IS THERE A GENDER DIFFERENCE?
  - P 76 PREDICTORS OF ALL-CAUSE MORTALITY IN PATIENTS WITH IMPLANTABLE CARDIAC DEVICES
  - P 78 GET WITH THE GUIDELINES - HEART FAILURE RISK SCORE: SHORT AND LONG TERM PREDICTIVE VALUE
  - P 79 VIRTUE LIES IN THE MIDDLE? OUTCOMES OF MID-RANGE EJECTION FRACTION AFTER ACUTE CORONARY SYNDROME
  - P 82 IMPACT OF A HEART FAILURE CLINIC IN MORBIDITY, MORTALITY AND QUALITY OF LIFE
- P 145 DAPAGLIFLOZIN IN A REAL-WORLD POPULATION WITH CHRONIC HEART FAILURE: HOW MANY WOULD BE ELIGIBLE?
- P 146 DOES ATRIAL FIBRILLATION INFLUENCE THE PERFORMANCE OF SURVIVAL SCORES FOR ADVANCED HEART FAILURE?
- P 149 PREDICTORS OF "RELAPSE" AFTER IMPROVED EJECTION FRACTION IN PATIENTS WITH HEART FAILURE
- P 152 GRACE SCORE IN ACUTE HEART FAILURE PATIENTS: AN ADDITIONAL VALUE?
- P 153 INTRAVENOUS FERRIC CARBOXIMALTOSE IN HEART FAILURE WITH PRESERVED OR INTERMEDIATE EJECTION FRACTION
- P 219 PULMONARY ARTERY SYSTOLIC PRESSURE: PROGNOSTIC FACTOR IN HEART FAILURE
- P 220 HEART FAILURE - PROGNOSTIC EVALUATION OF THE RETURN TO BASELINE NTPROBNP VALUE AT DISCHARGE
- P 221 LIMITING FACTORS FOR ACHIEVING MAXIMUM DOSE THERAPY IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- P 223 CLINICAL IMPACT OF NON-INVASIVE TELEMONITORING IN PATIENTS WITH CHRONIC HEART FAILURE

### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.3 CHRONIC HEART FAILURE - DIAGNOSTIC METHODS**

- P 74 CARDIOPULMONARY EXERCISE TESTING IN THE AGE OF NEW HEART FAILURE THERAPIES: STILL A POWERFUL TOOL?

### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.4 CHRONIC HEART FAILURE - TREATMENT**

- CO 45 THE HUGE IMPACT IN LEFT VENTRICULAR REVERSE REMODELING OF A SINGLE DRUG: A REAL-WORLD DATA WITH ARNI
- CO 46 LDL-C CUT-OFF IN HEART FAILURE- SHOULD WE FOLLOW THE GUIDELINES?

- P 80 6-HOURS LEVOSIMENDAN OUTPATIENT ADMINISTRATION IN ADVANCED HEART FAILURE: 93 SESSIONS EXPERIENCE
- P 81 SACUBITRIL/VALSARTAN: WHAT DOES THE REAL-LIFE EXPERIENCE TELL US?
- P 144 LEVOSIMENDAN THERAPY IN PATIENTS WITH ACUTELY DECOMPENSATED CHRONIC HEART FAILURE - OUTCOMES AND MORTALITY PREDICTORS
- P 150 INFLUENCE OF SACUBITRIL-VALSARTAN ON OUTCOMES OF PATIENTS WITH CHRONIC HEART FAILURE IN DIFFERENT POPULATIONS: BRAZIL AND PORTUGAL EXPERIENCE
- P 151 IMPACT OF SACUBITRIL-VALSARTAN ON CLINICAL-LABORATORIAL PARAMETERS, LEFT VENTRICLE EJECTION FRACTION AND LOOP DIURETIC DOSES OF PATIENTS WITH CHRONIC HEART FAILURE. BRAZIL AND PORTUGAL EXPERIENCE
- P 155 ANTAGONISTAS DOS RECEPTORES DA NEPRILISINA E ANGIOTENSINA NUMA CONSULTA DE IC
- P 218 PREDISPONENT FATORES TO GOOD RESPONSE TO EXERCISE
- P 230 LEFT ATRIAL MECHANICS IMPROVEMENT AFTER INITIATION OF SACUBITRIL-VALSARTAN

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.5 CHRONIC HEART FAILURE - PREVENTION**

- P 75 VALIDATION OF A HEART FAILURE RISK SCORE IN A REMOTE MONITORING COHORT

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.6 CHRONIC HEART FAILURE - CLINICAL**

- P 77 ADESÃO AO REGIME MEDICAMENTOSO NUMA CLÍNICA DE INSUFICIÊNCIA CARDÍACA
- P 147 AVALIAÇÃO DO ESTADO DE SAÚDE DE PACIENTES ACOMPANHADOS NUMA CLÍNICA DE INSUFICIÊNCIA CARDÍACA
- P 154 AVALIAÇÃO DA QUALIDADE DE VIDA DE DOENTES SEGUIDOS NUMA CLÍNICA DE INSUFICIÊNCIA CARDÍACA
- P 216 I-JOURNEY: PORTUGUESE DATA FROM AN ELECTRONIC SURVEY REGARDING HFPEF
- P 217 THYROID HORMONE LEVELS ARE NEGATIVELY ASSOCIATED WITH CLINICAL SEVERITY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.7 CHRONIC HEART FAILURE - OTHER**

- P 4 QUAL O IMPACTO DE INSTRUMENTOS DE AVALIAÇÃO NA EDUCAÇÃO DO DOENTE COM INSUFICIÊNCIA CARDÍACA?
- P 5 TELEMONITORIZAÇÃO NA IC: EXPERIÊNCIA DE UM CENTRO PORTUGUÊS
- P 148 MMSE/MOCA: ESTUDO COMPARATIVO NUMA UNIDADE DE INSUFICIÊNCIA CARDÍACA-RESULTADOS PRELIMINARES
- P 225 QUALITY OF LIFE OF HEART FAILURE PATIENTS IN PORTUGAL: A CROSS-SECTIONAL STUDY (PRIME STUDY)

#### **D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.2 ACUTE HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- CO 47 RISK STRATIFICATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: WHAT IS THE BEST SCORE?
- P 7 URIC ACID PROGNOSTIC IMPACT ON ACUTE HEART FAILURE
- P 10 PROGNOSTIC IMPACT OF ACUTE HEART FAILURE IN ACUTE CORONARY SYNDROME
- P 11 ACUTE HEART FAILURE: PULSE PRESSURE AS A PREDICTOR OF HOSPITALIZATION AND MORTALITY
- P 12 PROGNOSTIC IMPACT OF WORSENING RENAL FUNCTION IN B-TYPE ACUTE HEART FAILURE PATIENTS ON DECONGESTION
- P 222 EARLY RECURRENT CONGESTION AFTER AN ACUTE HEART FAILURE EVENT: EXPERIENCE FROM A DEDICATED CLINIC
- P 226 REAL LIFE HEART FAILURE POPULATION: SOMEWHAT DIFFERENT FROM THE REPORTS?
- P 289 MALNUTRITION IN ACUTE DECOMPENSATED HEART FAILURE
- P 290 CAN TAPSE/PSAP RATIO PREDICT MORTALITY AND RE-HOSPITALIZATION IN ACUTE HEART FAILURE PATIENTS?
- P 291 PREDICTING NON-INVASIVE VENTILATION FAILURE IN ACUTE HEART FAILURE PATIENTS PRESENTING IN THE EMERGENCY DEPARTMENT
- P 292 ECHO-AHF SCORE, A PREDICTIVE MODEL OF IN-HOSPITAL AND LONG-TERM MORTALITY IN HEART FAILURE

- P 293 HEMOCONCENTRATION IN ORDER TO AVOID READMISSIONS IN HEART FAILURE: WHICH LABORATORY MARKERS TO USE?
- P 294 POTASSIUM AS A PREDICTOR OF OUTCOME IN ACUTE HEART FAILURE AND PRESERVED EJECTION FRACTION
- P 299 PROFILE OF HOSPITALIZED PATIENTS WITH HEART FAILURE ADMITTED IN AN INTENSIVE CARE DEPARTMENT OF A TERTIARY CARE HOSPITAL

#### **D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.3 ACUTE HEART FAILURE - DIAGNOSTIC METHODS**

- P 288 CLINICAL AUDIT OF IN-PATIENT ECHOCARDIOGRAPHY IN ACUTE HEART FAILURE: REAL WORLD DATA FROM A TERTIARY HOSPITAL

#### **D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.4 ACUTE HEART FAILURE- TREATMENT**

- P 224 EARLY FOLLOW-UP VISIT BY A MULTIDISCIPLINARY HEART FAILURE TEAM AFTER ACUTE HEART FAILURE HOSPITALIZATION - IMPACT IN THE OUTCOMES
- P 227 IMPACT OF SPIRONOLACTONE IN HEART FAILURE WITH MID-RANGE EJECTION FRACTION: A FUTURE THERAPY?
- P 296 LEVOSIMENDAN IN ACUTE HEART FAILURE: A TERTIARY CENTER EXPERIENCE
- P 297 LEVOSIMENDAN INCREASES TIME OUT-OF-HOSPITAL IN DECOMPENSATED ADVANCED HEART FAILURE

#### **D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.7 ACUTE HEART FAILURE - OTHER**

- P 295 CHEST ULTRASOUND VERSUS NATRIURETIC PEPTIDES FOR THE DIFFERENTIAL DIAGNOSIS OF ACUTE CARDIAC DYSPNOEA
- P 298 AN OLD STIGMA IN ACUTE HEART FAILURE: WORSENING RENAL FUNCTION AT DISCHARGE IS ALWAYS A BIG ISSUE?

#### **E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.1 CORONARY ARTERY DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

- CO 13 LOWER GENETIC SCORE FOR CAD TRANSLATED IN IMPROVED SURVIVAL AND REDUCED ADVERSE CARDIOVASCULAR EVENTS
- P 102 HOMOCYSTEINE AS A PREDICTOR OF CARDIOVASCULAR ADVERSE EVENTS IN CORONARY ARTERY DISEASE
- P 105 INNATE IMMUNITY IS LINKED TO THE SEVERITY OF STABLE CORONARY ARTERY DISEASE THROUGH SCD40L PATHWAY
- P 107 INSIGHTS FROM MICRORNAs INTO THE PATHOPHYSIOLOGY OF CORONARY AND MULTITERRITORIAL ATHEROSCLEROSIS

#### **E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.2 CORONARY ARTERY DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- P 115 CLINICAL EVIDENCE FOR INCREASED CARDIOVASCULAR MORTALITY AND LATE ADVERSE EVENTS WITH LOW HDL LEVELS
- P 116 INFLUENCE OF A GENETIC OXIDATIVE PREDISPOSITION SCORE ON HDL-CHOLESTEROL
- P 119 A GENETIC RISK SCORE PREDICTS CARDIOVASCULAR MORTALITY IN YOUNG ADULTS WITH CORONARY HEART DISEASE

#### **E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.3 CORONARY ARTERY DISEASE - DIAGNOSTIC METHODS**

- P 104 IS CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY A GOOD CHOICE FOR ELDERLY AND HIGH PROBABILITY CASES?
- P 106 STRESS ECHOCARDIOGRAPHY WITH 2019 UPDATED PRE-TEST PROBABILITIES - LOVE OR HATE?
- P 118 TRANSRADIAL VERSUS TRANFEMORAL ACCESS FOR CORONARY ANGIOGRAPHY IN POST-CABG PATIENTS: A RETROSPECTIVE COMPARATIVE STUDY

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE****-> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.4 CORONARY ARTERY DISEASE - TREATMENT**

- CO 16 PATTERNS OF REVASCLARIZATION IN STABLE ISCHEMIC HEART DISEASE IN THE PRE-ISCHEMIA ERA
- CO 17 THE POTENTIAL BENEFIT OF THE EPICARDIAL LEFT VENTRICULAR LEAD IN ISCHEMIC CARDIOMIOPATHY
- P 117 MANAGEMENT OF CHRONIC CORONARY SYNDROMES: DEVELOPING MATHEMATICS TO CALCULATE RISK IN PERCUTANEOUS REVASCLARIZATION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE****-> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.6 CORONARY ARTERY DISEASE - CLINICAL**

- P 103 PREDICTORS OF HIGH AND LOW SERUM HDL-CHOLESTEROL IN A PORTUGUESE POPULATION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE****-> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.7 NON-ATHEROSCLEROTIC CORONARY ABNORMALITIES**

- P 114 CORONARY ARTERY FISTULAS: A SINGLE-CENTER CASE SERIES

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC****CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.1 ACUTE CORONARY SYNDROMES - PATHOPHYSIOLOGY AND MECHANISMS**

- P 33 DIABETES AND PRE-INFARCT ANGINA. TIME TO RETHINK COMORBIDITIES IN THE REPERFUSION-INJURY PHENOMENON?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE****-> 13. ACUTE CORONARY SYNDROMES -> 13.2 ACUTE CORONARY SYNDROMES - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- P 30 PREDICTORS OF ADVERSE IN-HOSPITAL PROGNOSIS IN NSTEMI WITH RBBB
- P 31 GLOBAL LONGITUDINAL STRAIN: THE NEW LEFT VENTRICULAR EJECTION DURING AN ACUTE CORONARY SYNDROME?
- P 32 ACUTE MYOCARDIAL INFARCTION RISK FACTORS AND SYMPTOMS: WHAT DOES THE PORTUGUESE POPULATION KNOW?
- P 35 LONG TERM IMPACT OF OBSTRUCTIVE SLEEP APNEA IN PATIENTS WITH ACUTE CORONARY SYNDROME
- P 43 PROGNOSIS OF COMPLETE VERSUS INCOMPLETE REVASCLARIZATION IN DIABETIC PATIENTS AFTER STEMI
- P 110 PRECISE-DAPT SCORE FOR LONG-TERM BLEEDING PREDICTION AFTER ACUTE CORONARY SYNDROME
- P 112 PREMATURE ACUTE CORONARY SYNDROME
- P 113 MEAN PLATELET VOLUME AS A PREDICTOR OF IN-HOSPITAL COMPLICATIONS IN ACUTE CORONARY SYNDROMES
- P 174 MODIFIED ZWOLLE SCORE WITH DELTA-CREATININE: ENHANCED SAFETY OF EARLY DISCHARGE AFTER STEMI
- P 175 GLOBAL LONGITUDINAL STRAIN: THE BEST AT PREDICTING NT-PROBNP LEVELS IN ACUTE CORONARY SYNDROME?
- P 177 DISCRIMINATORY POWER OF GRACE SCORE IN NSTEMI IN THE REAL-WORLD: RESULTS FROM THE PORTUGUESE REGISTRY ON ACUTE CORONARY SYNDROMES
- P 178 PROGNOSTIC IMPACT OF INTRAVENTRICULAR CONDUCTION DEFECTS IN PATIENTS WITH STEMI
- P 180 PREDICTORS OF BLEEDING IN ELDERLY PATIENTS WITH MYOCARDIAL INFARCTION: DATA FROM THE REAL WORLD
- P 181 PROGNOSTIC VALUE OF THE CHA2DS2VASC SCORE IN ACUTE CORONARY SYNDROME WITHOUT ATRIAL FIBRILLATION
- P 183 EARLY AND LATE ONSET DE NOVO ATRIAL FIBRILLATION IN ACUTE CORONARY SYNDROME
- P 184 IMPACT OF PRO-THROMBOTIC, ANTIOXIDANT PLASMA STATUS ON PROGNOSIS AFTER ACUTE CORONARY SYNDROME (ACS)
- P 186 LEFT VENTRICULAR DYSFUNCTION IN EARLY PRIMARY ANGIOPLASTY: CHARACTERIZATION AND PREDICTORS
- P 187 PREDICTORS OF ADVERSE PROGNOSIS AT FOLLOW-UP IN NSTEMI WITH RBBB

- P 189 DAY VERSUS NIGHT SHIFT DIFFERENCES IN ACUTE CORONARY SYNDROME OUTCOMES
- P 246 ACUTE CORONARY SYNDROME FOLLOWING PRIOR PCI OR CABG - ARE ALL PATIENTS THE SAME?
- P 247 ACUTE TO CHRONIC GLYCEMIC RATIO CLINICAL VALUE IN ACUTE CORONARY SYNDROME
- P 248 METEOROLOGICAL TRIGGERING OF ST-ELEVATION MYOCARDIAL INFARCTION
- P 252 IS TERRITORIAL LONGITUDINAL STRAIN ABLE TO PREDICT THE CORONARY ARTERY DISEASE CULPRIT LESION IN ACUTE CORONARY SYNDROMES?
- P 255 OPTIMAL TIMING OF INVASIVE STRATEGY IN PATIENTS WITH DIABETES AND NSTEMI-ACS
- P 257 SMOKERS' PARADOX IN ACUTE CORONARY SYNDROME: REALITY OR FICTION?
- P 260 GLOBAL LONGITUDINAL STRAIN AS A PREDICTOR OF CARDIOVASCULAR EVENTS AND MORTALITY AFTER MYOCARDIAL INFARCTION
- P 263 NEW ONSET PAROXYSMAL ATRIAL FIBRILLATION OCCURRENCE DURING HOSPITAL ADMISSION FOR ACUTE MYOCARDIAL INFARCTION IS NOT ASSOCIATED WITH ATRIAL FIBRILLATION RECURRENCE DURING FOLLOW-UP
- P 318 CHRONIC KIDNEY DISEASE IN ACUTE CORONARY SYNDROMES: WHAT IS THE REAL BURDEN?
- P 319 HEMORRHAGIC RISK SCORES IN ACUTE CORONARY SYNDROMES: PREDICTION OF IN-HOSPITAL BLEEDING COMPLICATIONS
- P 320 FRIEND OR FOE: ACUTE CORONARY SYNDROME WITHOUT STANDARD MODIFIABLE CARDIOVASCULAR RISK FACTORS
- P 321 ECG TO REPERFUSION TIME ANALYSIS AND ITS IMPACT IN THE PROGNOSIS OF ACUTE MYOCARDIAL INFARCTION
- P 323 PROGNOSTIC VALUE OF ANEMIA AT HOSPITAL ADMISSION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION

## **E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE**

### **-> 13. ACUTE CORONARY SYNDROMES -> 13.3 ACUTE CORONARY SYNDROMES - DIAGNOSTIC METHODS**

- P 250 EPICARDIAL FAT TISSUE: A NEW TOOL FOR IDENTIFICATION OF CORONARY ARTERY DISEASE PATIENTS?
- P 251 PEAK VERSUS AREA UNDER THE CURVE OF CARDIAC TROPONIN I VALUES FOR ESTIMATION OF INFARCT SIZE

## **E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE**

### **-> 13. ACUTE CORONARY SYNDROMES -> 13.4 ACUTE CORONARY SYNDROMES - TREATMENT**

- CO 12 EVOLUTION OF IN-HOSPITAL MANAGEMENT IN ST SEGMENT ELEVATION MYOCARDIAL INFARCTION IN PORTUGUESE HOSPITALS OVER THE YEARS
- P 34 SHOULD WE STILL USE BETA-BLOCKERS IN ALL PATIENTS AFTER ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION?
- P 45 ANTICOAGULATION IN PATIENTS WITH NEW-ONSET ATRIAL FIBRILLATION AFTER ACUTE CORONARY SYNDROME
- P 46 FRACTIONAL FLOW RESERVE-GUIDED ANGIOPLASTY PREDICTS ACUTE CORONARY SYNDROMES IN PREVIOUSLY NON-STENTED VESSELS
- P 108 IS THE EARLY INVASIVE STRATEGY REALLY THE OPTIMAL TIME FOR PATIENTS AT HIGH-RISK OF ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
- P 109 IMPROVED OUTCOMES AFTER INVASIVE STRATEGY IN FRAIL NON-ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS
- P 179 PARENTAL ANTICOAGULATION IN NON-ST ELEVATION ACUTE CORONARY SYNDROMES: ENOXAPARIN VERSUS FONDAPARINUX
- P 182 TICAGRELOR PRETREATMENT IN INVASIVELY MANAGED PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROME
- P 185 MULTIVESSEL VERSUS CULPRIT-ONLY REVASCULARIZATION IN NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME
- P 188 LEFT MAIN DISEASE ANGIOPLASTY: A REAL-LIFE EXPERIENCE
- P 190 REPERFUSION AFTER STEMI: IS THERE A TREATMENT DELAY IN WOMEN OR ELDERLY AFTER THE DIAGNOSTIC ECG?
- P 253 EVOLUTION OF HOSPITAL DISCHARGE MEDICATION AND 6 MONTHS OUTCOMES OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS IN PORTUGAL OVER THE YEARS
- P 254 FRAILTY AND ST-ELEVATION MYOCARDIAL INFARCTION - IMPROVED OUTCOMES AFTER AN INVASIVE STRATEGY

- P 262 FIVE YEARS EXPERIENCE OF DRUG-COATED BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY ARTERY DISEASE
- P 322 PROGNOSIS OF REVASCLARAZION ON A PREVIOUS MYOCARDIAL INFRACTION (MI), IN PATIENTS WHO PRESENT WITH A NEW ACUTE CORONARY SYNDROME (ACS).

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE  
-> 13. ACUTE CORONARY SYNDROMES -> 13.5 ACUTE CORONARY SYNDROMES - PREVENTION**

- P 176 IMPACT OF PRE-TREATMENT WITH ACETYLSALICYLIC ACID ON THE SEVERITY OF A FIRST MYOCARDIAL INFARCTION IN DIABETIC PATIENTS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE  
-> 13. ACUTE CORONARY SYNDROMES -> 13.7 ACUTE CORONARY SYNDROMES - OTHER**

- P 38 RESUSCITATED CARDIAC ARREST AND NO ST-ELEVATION - WHAT TO EXPECT?
- P 191 CARDIOGENIC SHOCK DUE TO ACUTE CORONARY SYNDROME: CHARACTERISTICS AND OUTCOMES
- P 249 PREDICTORS AND OUTCOMES OF INFECTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION
- P 256 HAEMORRHAGIC RISK OF ONCOLOGY PATIENTS WITH MYOCARDIAL INFARCTION
- P 258 BLEEDING PREDICTORS IN ACUTE CORONARY SYNDROME: DOES THE AGE OR CLINICAL PRESENTATION MATTERS?
- P 259 ACUTE CORONARY SYNDROME AND STRESS: IS THERE A RELATIONSHIP?
- P 261 GENDER IN NON- ST ELEVATION MYOCARDIAL INFARCTION AND UNSTABLE ANGINA: IS THERE ANY EQUALITY?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE  
-> 14. ACUTE CARDIAC CARE -> 14.1 ACUTE CARDIAC CARE - RESUSCITATION**

- P 41 THE IMPACT OF A CLINICAL PROTOCOL IN THE MANAGEMENT OF THE RESUSCITATED CARDIAC ARREST PATIENTS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE  
-> 14. ACUTE CARDIAC CARE -> 14.2 ACUTE CARDIAC CARE - PREHOSPITAL AND EMERGENCY DEPARTMENT CARE**

- P 37 INITIALLY ELEVATED TROPONIN I IN RAPID ATRIAL FIBRILLATION SHOULD LEAD TO CORONARY ANGIOGRAPHY
- P 44 TICAGRELOR TREATMENT STRATEGIES COMPARATIVE ANALYSIS IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE  
-> 14. ACUTE CARDIAC CARE -> 14.3 ACUTE CARDIAC CARE - CCU, INTENSIVE, AND CRITICAL CARDIOVASCULAR CARE**

- P 111 PREDICTORS OF NEED OF NON-INVASIVE VENTILATION IN ACUTE CORONARY SYNDROME

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE  
-> 14. ACUTE CARDIAC CARE -> 14.4 ACUTE CARDIAC CARE - CARDIOGENIC SHOCK**

- P 8 CARDIOGENIC SHOCK WITHOUT SEVERE VENTRICULAR DYSFUNCTION IN STELEVATION ACUTE MYOCARDIAL INFARCTION
- P 9 REVASCLARIZATION STRATEGIES IN CONTEXT OF ACUTE CORONARY SYNDROME PRESENTING WITH CARDIOGENIC SHOCK
- P 36 SEVERE VENTRICULAR DYSFUNCTION AFTER STEMI COMPLICATED BY CARDIOGENIC SHOCK: PREDICTORS, PROGNOSIS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE****-> 14. ACUTE CARDIAC CARE -> 14.5 ACUTE CARDIAC CARE - CARDIAC ARREST**

P 39 PARAGEM CARDIORRESPIRATÓRIA INTRA-HOSPITALAR E NSTEMI: SERÁ POSSÍVEL IDENTIFICAR OS DOENTES EM RISCO?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 15. VALVULAR HEART DISEASE -> 15.1 VALVULAR HEART DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

P 344 THE MECHANICS BEYOND BICUSPID AORTIC VALVE

CO 62 LV REPLACEMENT FIBROSIS IN AORTIC STENOSIS: PREVALENCE AND RELATION TO LV REMODELLING AND FUNCTION

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 15. VALVULAR HEART DISEASE -> 15.2 VALVULAR HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

CO 64 LEFT ATRIAL EMPTYING FRACTION: A POWERFUL PREDICTOR OF EVENTS IN SEVERE AORTIC STENOSIS

P 48 CARDIAC DAMAGE IN A REAL-WORLD SEVERE AORTIC STENOSIS POPULATION

P 49 EXTERNAL VALIDATION OF A NEW STAGING SYSTEM FOR SEVERE AORTIC STENOSIS IN A PORTUGUESE COHORT

P 55 WHAT IS THE RISK OF A PATIENT WITH SEVERE AORTIC STENOSIS WHILE WAITING FOR AORTIC VALVE INTERVENTION?

P 120 GLOBAL LONGITUDINAL STRAIN INDICES PRIOR TO AORTIC SUBSTITUTION PREDICTS POST INTERVENTION OUTCOMES

P 122 CONTEMPORARY CORONARY ARTERY DISEASE PREVALENCE IN A VALVULAR HEART DISEASE POPULATION UNDERGOING SURGERY

P 123 PREDICTORS OF MORTALITY IN MITRAL VALVE PROLAPSE

P 124 MITRAL VALVE PROLAPSE - CAN WE STRATIFY PROGNOSIS IN THESE PATIENTS?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 15. VALVULAR HEART DISEASE -> 15.3 VALVULAR HEART DISEASE - DIAGNOSTIC METHODS**

P 51 DETERMINANTS OF EXERCISE TOLERANCE IN AORTIC STENOSIS

P 121 RELATIVE APICAL SPARING IN PATIENTS WITH SEVERE AORTIC STENOSIS: PREVALENCE AND SIGNIFICANCE

P 126 USEFULNESS OF CARDIAC CT SCAN IN PATIENTS WITH UNDETERMINED AORTIC PROSTHESIS DYSFUNCTION

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 15. VALVULAR HEART DISEASE -> 15.4 VALVULAR HEART DISEASE - TREATMENT**

P 53 SEVERE AORTIC STENOSIS IN OCTOGENARIANS - IS SURGICAL AORTIC VALVE REPLACEMENT A GOOD OPTION?

P 54 PERFORMANCE OF SURGICAL RISK SCORES PREDICTING SHORT- AND LONG-TERM MORTALITY FOLLOWING TAVI IN PATIENTS WITH ACUTE HEART FAILURE

P 57 LONG TERM DURABILITY OF SELF-EXPANDING TRANSCATHETER AORTIC VALVE PROSTHESES

P 58 CHARACTERISTICS AND OUTCOMES OF VERY OLD PATIENTS WHO UNDERWENT TAVI-EXPERIENCE OF A TERTIARY CENTER

P 59 SECONDARY ACCESS FOR TAVI: RADIAL OR FEMORAL ARTERY IN MINIMALIST TAVI?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 15. VALVULAR HEART DISEASE -> 15.6 VALVULAR HEART DISEASE - CLINICAL**

P 125 MITRAL VALVE PROLAPSE: AMERICAN VERSUS EUROPEAN GUIDELINES - WHICH ONE IS BETTER

CO 63 OUTCOMES AFTER AORTIC VALVE REPLACEMENT: MECHANICAL VERSUS BIOPROSTHETIC VALVES IN PATIENTS 50-70 YEARS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 15. VALVULAR HEART DISEASE -> 15.7 VALVULAR HEART DISEASE - OTHER**

P 56 AORTIC VALVE CALCIUM SCORE PRE-TAVI: IS 3MENSIO® SOFTWARE AN ALTERNATIVE TO THE AGATSTON SCORE?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 16. INFECTIVE ENDOCARDITIS -> 16.2 INFECTIVE ENDOCARDITIS - EPIDEMIOLOGY, PROGNOSIS,  
OUTCOME**

P 131 MORTALITY RATE FROM INFECTIVE ENDOCARDITIS IN THE LAST 20 YEARS IN PORTUGAL

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 17. MYOCARDIAL DISEASE -> 17.1 MYOCARDIAL DISEASE - PATHOPHYSIOLOGY  
AND MECHANISMS**

CO 18 INFLAMMATORY INFILTRATE DRIVES MYOCARDIAL INJURY IN HUMAN SEPTIC CARDIOMYOPATHY

CO 19 ASSOCIATION BETWEEN MICROCIRCULATORY DYSFUNCTION AND IMPAIRED MYOCARDIAL DEFORMATION IN HYPERTROPHIC CARDIOMYOPATHY

CO 20 STAGES OF CARDIAC INVOLVEMENT IN PRE-HYPERTROPHIC FABRY DISEASE: AN INTEGRATED ELECTROCARDIOGRAPHIC AND CARDIOVASCULAR MAGNETIC RESONANCE APPROACH

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 17. MYOCARDIAL DISEASE -> 17.2 MYOCARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS,  
OUTCOME**

P 192 PROGNOSTIC IMPACT OF SUSPECTED CARDIAC AMYLOIDOSIS IN AORTIC STENOSIS PATIENTS REFERRED FOR TRANSCATHETER AORTIC VALVE IMPLANTATION

P 193 PREDICTORS OF HEART FAILURE IN LEFT VENTRICULAR NONCOMPACTION

P 199 CLINICAL DESCRIPTION AND FOLLOW-UP OF ADULT HYPERTROPHIC CARDIOMYOPATHY PATIENTS

P 201 LATE GADOLINIUM ENHANCEMENT AS A PREDICTOR OF ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

P 265 PREDICTORS OF ATRIAL FIBRILLATION OCCURRENCE IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

P 267 LONG-TERM FOLLOW-UP OF ICD THERAPIES IN HYPERTROPHIC CARDIOMYOPATHY: A LARGE SINGLE CENTRE EXPERIENCE

P 268 DESCRIBING MYOCARDITIS IN THE ERA OF CARDIAC MRI

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 17. MYOCARDIAL DISEASE -> 17.3 MYOCARDIAL DISEASE - DIAGNOSTIC METHODS**

CO 21 LEFT VENTRICLE TRANSRADIAL ENDOMYOCARDIAL BIOPSY: INITIAL EXPERIENCE OF A TERTIARY CENTER

CO 23 RELATIONSHIP BETWEEN MICROCIRCULATORY DYSFUNCTION, MYOCARDIAL FIBROSIS AND ARRHYTHMIAS IN HYPERTROPHIC CARDIOMYOPATHY

P 196 BONE SCINTIGRAPHY IN THE DIAGNOSIS OF MTTR AMYLOIDOSIS: DIFFERENT PERFORMANCE IN PORTUGUESE VARIANT?

P 197 ECHOCARDIOGRAPHY PARAMETERS FOR DIFFERENTIAL DIAGNOSIS IN PATIENTS WITH SUSPECTED CARDIAC AMYLOIDOSIS

P 200 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY OPPORTUNISTIC DIAGNOSIS: WHERE'S WALLY?

P 202 CARDIAC MAGNETIC RESONANCE EVALUATION AND CHARACTERIZATION OF FEATURES OF CARDIAC SARCOIDOSIS

P 269 ECG CHANGES AND LEFT VENTRICULAR HYPERTROPHY CRITERIA IN HYPERTROPHIC CARDIOMYOPATHY PHENOTYPES

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 17. MYOCARDIAL DISEASE -> 17.4 MYOCARDIAL DISEASE - TREATMENT**

P 194 SURGICAL MYECTOMY FOR HYPERTROFIC OBSTRUCTIVE CARDIOMYOPATHY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 17. MYOCARDIAL DISEASE -> 17.6 MYOCARDIAL DISEASE - CLINICAL**

P 198 HYPERTROPHIC CARDIOMYOPATHY IN THE ELDERLY - DOES AGE MATTER?

P 203 ROLE OF CONDUCTION ABNORMALITIES IN HYPERTROPHIC CARDIOMYOPATHY

P 264 BEING A WOMAN - A DISADVANTAGE IN APICAL HYPERTROPHIC CARDIOMYOPATHY?

P 266 TRANSTHYRETIN CARDIAC AMYLOIDOSIS: INSIGHTS FROM A TERTIARY HOSPITAL

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 17. MYOCARDIAL DISEASE -> 17.7 MYOCARDIAL DISEASE - OTHER**

P 195 MEASUREMENT OF MAXIMUM LV WALL THICKNESS BY CMR AND ECHOCARDIOGRAPHY AND ITS IMPACT IN HCM RISK-SCD

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 18. PERICARDIAL DISEASE -> 18.2 PERICARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

CO 22 ACUTE PERICARDITIS: SHOULD I STAY OR SHOULD I GO?

P 130 CONSTRICTIVE PERICARDITIS: STILL A DIFFICULT DIAGNOSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 19. TUMORS OF THE HEART -> 19.2 TUMORS OF THE HEART - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

P 128 PRIMARY AND SECONDARY MALIGNANT CARDIAC TUMORS - A 22 YEAR CASE REVIEW

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.2 CONGENITAL HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

P 340 OUT-OF-HOSPITAL PAEDIATRIC CARDIORESPIRATORY ARREST - 13-YEAR EXPERIENCE

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.3 CONGENITAL HEART DISEASE - DIAGNOSTIC METHODS**

CO 32 CARDIOPULMONARY EXERCISE TESTING IN REPAIRED TETRALOGY OF FALLOT - ASSESSING PULMONARY REGURGITATION

P 343 GLOBAL CIRCUNFERENCIAL STRAIN AS A PREDICTOR OF DISEASE PROGRESSION IN PATIENTS WITH BICUSPID AORTIC VALVES

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE****-> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.4 CONGENITAL HEART DISEASE - TREATMENT**

CO 31 NEW ONSET ATRIAL FIBRILLATION AFTER PERCUTANEOUS PATENT FORAMEN OVALE CLOSURE - HOW SERIOUS IS THIS PROBLEM?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.6 CONGENITAL HEART  
DISEASE - CLINICAL**

P 129 INFECTIVE ENDOCARDITIS IN A COHORT OF ADULT CONGENITAL HEART DISEASE PATIENTS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.8 CONGENITAL HEART  
DISEASE AND PEDIATRIC CARDIOLOGY - OTHER**

P 338 DOES AGE AT AORTIC COARCTATION REPAIR HAVE AN IMPACT ON LEFT VENTRICLE SIZE AND FUNCTION?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE  
-> 21.2 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -  
EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

CO 30 TEMPO ATÉ TERAPÊUTICA FIBRINOLÍTICA NO TEP, QUAL O IMPACTO PROGNÓSTICO?

CO 34 PREDICTORS OF PERSISTENT PULMONARY HYPERTENSION AFTER PULMONARY ENDARTERECTOMY IN CTEPH

P 272 PREDICTORS OF SURVIVAL IN PATIENTS WITH PRECAPILLARY PULMONARY HYPERTENSION

P 274 PREDICTING ADVERSE EVENTS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE REVEAL RISK SCORE 2.0 AND ESC/ERS-BASED RISK ASSESSMENT STRATEGIES

P 275 HAEMODYNAMIC ASSESSMENT OF RIGHT VENTRICULAR OVERLOAD IN PULMONARY HYPERTENSION: IS IT TIME FOR NEW PREDICTORS?

P 336 PROGNOSIS OF PULMONARY EMBOLISM: 30-DAY MORTALITY RISK BASED ON THREE ADMISSION PARAMETERS - THE POPE SCORE

P 337 FAST-RVD SCORE, A BETTER PREDICTOR OF IN-HOSPITAL MORTALITY IN ACUTE PULMONARY EMBOLISM?

P 339 PULMONARY ENDARTERECTOMY IN CTEPH: CLINICAL AND HEMODYNAMIC LONG TERM EFFECT

P 341 THE ROLE OF CARDIAC BIOMARKERS ELEVATION IN INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM

P 346 RIGHT ATRIAL MECHANICS BY STRAIN ECHOCARDIOGRAPHY IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE  
-> 21.3 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - DIAGNOSTIC  
METHODS**

P 347 RIGHT TO LEFT VENTRICULAR DIAMETER RATIO ON PULMONARY ANGIO-CT. IS THERE A CORRELATION WITH HEMODYNAMICS IN CTEPH?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE  
-> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE  
-> 21.4 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - TREATMENT**

CO 33 EFFECTIVENESS AND SAFETY OF BALLOON PULMONARY ANGIOPLASTY IN A SMALL COHORT OF CTEPH PATIENTS

CO 35 BALLOON PULMONARY ANGIOPLASTY 6 MONTHS RESULTS: SHORT TERM PERFORMANCE OF THE NEW KID ON THE BLOCK FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE  
-> 22.3 AORTIC DISEASE - DIAGNOSTIC METHODS**

P 50 LEFT VENTRICULAR REMODELLING IN AORTIC STENOSIS: PREDICTION FROM ECG CRITERIA

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 23. PERIPHERAL VASCULAR AND CEREBROVASCULAR DISEASE -> 23.1 PERIPHERAL VASCULAR AND CEREBROVASCULAR DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

P 141 DEGREES OF SCD40L PATHWAY ACTIVATION IN CORONARY AND MULTITERRITORIAL ATHEROSCLEROSIS

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 24. STROKE -> 24.1 STROKE - PATHOPHYSIOLOGY AND MECHANISMS**

P 349 IS TROPONIN RELATED TO STROKE ETHIOLOGY?

P 351 PATENT FORAMEN OVALE: THE BALANCE BETWEEN ROPE SCORE AND ECHOCARDIOGRAPHIC CHARACTERISTICS

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 24. STROKE -> 24.2 STROKE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

P 348 CAN NT-PROBNP PREDICT FUNCTIONAL OUTCOME AFTER A STROKE?

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 24. STROKE -> 24.3 STROKE - DIAGNOSTIC METHODS**

P 352 ATRIAL FIBRILLATION RISK STRATIFICATION AFTER ISCHEMIC STROKE - WHAT CAN BE DONE WITH USUAL WORK UP DIAGNOSTIC TOOLS

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 24. STROKE -> 24.7 HEART AND BRAIN INTERACTION**

P 350 CAN LEFT ATRIAL MECHANICS PREDICT ANTICOAGULATION IN CRYPTOGENIC STROKE?

P 353 PATENT FORAMEN OVALE - HIGH-RISK ECHOCARDIOGRAPHIC FEATURES RELATED TO SECONDARY STROKE PREVENTION

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.1 INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT**

P 278 IMPACT OF THE IFR CO-REGISTRATION PULLBACK SYSTEM ON REVASCLARIZATION

P 279 TEMPORAL TRENDS IN PHYSIOLOGY CORONARY INDEXES AND THEIR IMPACT ON REVASCLARIZATION

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.2 CORONARY INTERVENTION**

CO 49 INTRAVASCULAR ULTRASOUNDS IN PORTUGAL: USAGE TREND AND OUTCOMES

CO 51 PROGNOSTIC IMPACT OF CORONARY ARTERY DISEASE SEVERITY AND REVASCLARIZATION IN TAVI PATIENTS

CO 52 CORONARY CHRONIC TOTAL OCCLUSIONS: 8-YEAR EXPERIENCE FROM A DEDICATED SINGLE-CENTER PROGRAM

P 132 SNOPI SCORE (SCORE OF NO-REFLOW IN PRIMARY ANGIOPLASTY) AS A PREDICTOR OF NO-REFLOW PHENOMENA AFTER PRIMARY ANGIOPLASTY

P 133 RISK STRATIFICATION IN UNPROTECTED LEFT MAIN CORONARY DISEASE: DO WE HAVE THE TOOLS?

P 134 BIFURCATION PCI - EXPERIENCE FROM A SINGLE CENTER

P 135 CORONARY BIFURCATION LESIONS: A BIRD IN THE HAND VERSUS TWO IN THE BUSH

P 136 ONE STENT VERSUS TWO STENTS FOR DISTAL LM PCI: INSIGHTS FROM THE EXPERIENCE OF A HIGH VOLUME CENTER

P 137 DEDICATED STENTS FOR CORONARY BIFURCATION LESIONS: PRECISION MEDICINE VERSUS PRECISION ENGINEERING

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.3 NON-CORONARY CARDIAC INTERVENTION**

- CO 40 PREDICTING PACEMAKER IMPLANTATION AFTER TAVR WITH PROCEDURAL CT
- CO 53 PORTUGUESE SINGLE CENTRE EXPERIENCE IN PERCUTANEOUS CATHETER-DIRECTED TREATMENT FOR ACUTE PULMONARY EMBOLISM: IS TIME FOR A LUNG FAST-TRACK SYSTEM (“VIA VERDE PULMONAR”)?
- CO 65 CONDUCTION DISTURBANCES AFTER TAVI - REAL-LIFE DATA FROM A PORTUGUESE CENTER
- P 205 TEMPORAL TRENDS AND OUTCOMES AFTER TAVI: WHAT WE’VE LEARNED OVER THE PAST DECADE
- P 206 PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE: A 10-YEAR EXPERIENCE
- P 207 EARLY DISCHARGE AFTER TAVI: SHOULD WE STILL BE AFRAID OF CONDUCTION DISTURBANCES?
- P 276 REDUCER, THE NEW KID ON THE BLOCK FOR REFRACTORY ANGINA THERAPY - A SINGLE CENTER EXPERIENCE
- P 277 FEASIBILITY AND SAFETY OF THE ANTECUBITAL VENOUS ACCESS FOR RIGHT HEART CATHETERIZATION IN PATIENTS WITH PULMONARY HYPERTENSION
- P 280 CONDUCTION DISTURBANCES IN VERY OLD PATIENTS AFTER TAVI
- P 281 AORTIC STENOSIS SUBTYPES: IMPACT ON TAVR OUTCOMES

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.4 INTERVENTIONAL CARDIOLOGY - OTHER**

- CO 48 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE AORTIC STENOSIS
- P 204 VASCULAR CLOSURE DEVICES IN TAVI: MANTA® VERSUS PROGLIDE® IN A PROPENSITY-MATCHED POPULATION

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.1 CARDIOVASCULAR SURGERY - CORONARY ARTERIES**

- P 60 MULTIPLE VERSUS SINGLE ARTERIAL GRAFTING IN CORONARY SURGERY AMONG DIABETIC PATIENTS: A META-ANALYSIS
- P 61 DUAL ANTIPLATELET THERAPY VERSUS ASPIRIN MONOTHERAPY AFTER CABG: SHORT AND LONG-TERM SURVIVAL
- P 63 EFFECT OF PRE-OPERATIVE  $\beta$ -BLOCKER THERAPY AFTER CABG SURGERY: LONG-TERM SURVIVAL AND POSTOPERATIVE COMPLICATIONS
- P 64 THE IMPACT OF RENAL FUNCTION ON CARDIAC SURGERY- 3-YEAR EXPERIENCE OF A REFERRAL CENTER
- P 65 TO CBP OR NOT TO CBP: WHICH PATIENTS GREATER BENEFIT FROM AN OFF-PUMP CABG STRATEGY?

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.10 CARDIOVASCULAR SURGERY - MINIMALLY INVASIVE SURGERY**

- CO 50 TRANSAPICAL OFF-PUMP MITRAL VALVE REPAIR WITH NEOCHORD IMPLANTATION: EARLY CLINICAL AND ECHOCARDIOGRAPHIC RESULTS

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.11 CARDIOVASCULAR SURGERY - OTHER**

- P 62 TEN YEARS OF EXTENDED MYECTOMY FOR THE TREATMENT OF HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
- P 208 IN AND OUT - WHAT IS THE REAL IMPACT OF THE “WAITING SETTING” IN CARDIAC SURGICAL PATIENTS?
- P 209 ARE OUR PATIENTS WAITING TOO LONG FOR CARDIAC SURGERY?

**I. HYPERTENSION -> 27. HYPERTENSION -> 27.2 HYPERTENSION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- P 324 POLYMORPHISM OF THE EPITHELIAL SODIUM CHANNEL SCNN1G G(-173)A IS ASSOCIATED WITH THE HYPERTENSIVE HEART DISEASE

- P 325 THE ROLE OF A GENETIC RISK SCORE FOR PREDICTING TARGET ORGAN DAMAGE IN HYPERTENSIVE PATIENTS  
 P 328 SHOULD WE REDEFINE HYPERTENSIVE RESPONSE IN STRESS TEST TO BETTER PREDICT CARDIOVASCULAR RISK?

## **I. HYPERTENSION -> 27. HYPERTENSION -> 27.3 HYPERTENSION - DIAGNOSTIC METHODS**

- P 329 HYPERTENSIVE RESPONSE IN EXERCISE - A TOOL TO PREDICT STROKE RISK?

## **I. HYPERTENSION -> 27. HYPERTENSION -> 27.4 HYPERTENSION - TREATMENT**

- P 326 DISLIPIDEMIA E HIPERTENSAO. O FOLLOW-UP DE ESTRATEGIAS TERAPEUTICAS DE DUAS DECADAS!

## **I. HYPERTENSION -> 27. HYPERTENSION -> 27.6 HYPERTENSION - CLINICAL**

- P 327 BLOOD PRESSURE AND ARTERIAL STIFFNESS IN SICKLE CELL DISEASE (SCD) WITH (HT) AND WITHOUT HYPERTENSION (NHT)

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.1 RISK FACTORS AND PREVENTION - EPIDEMIOLOGY**

- P 70 E\_COR STUDY: PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN THE PORTUGUESE POPULATION

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.2 RISK FACTORS AND PREVENTION - CARDIOVASCULAR RISK ASSESSMENT**

- P 66 COIMBRA UNITED BY THE HEART: COMMUNITY-BASED PROJECT FOR THE PREVENTION OF CARDIOVASCULAR DISEASES  
 P 69 IS BUD13-ZNF259 GENE VARIANT A RISK FACTOR FOR CORONARY PORTUGUESE POPULATION?  
 P 71 HYPERTENSIVE RESPONSE TO EXERCISE - TO TREAT OR NOT TO TREAT?  
 P 140 TCF21 VARIANT IS A RISK FACTOR FOR CORONARY ARTERY DISEASE AND WILL IT BE A PROGNOSTIC MARKER?  
 P 142 ACUTE MYOCARDIAL INFARCTION AT = 50 YEARS OLD- INADEQUATE CORONARY RISK PREDICTION AND RISK FACTORS CONTROL

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.3 SECONDARY PREVENTION**

- P 67 CAROTID-FEMORAL PULSE WAVE VELOCITY ASSESSMENT IN MACE RISK PREDICTION IN CORONARY PATIENTS  
 P 139 SHAPING THE FUTURE OF METABOLIC SYNDROME: GENETICS, PROGNOSIS AND INDIVIDUAL TAILORING  
 P 143 PREDICTORS OF NEW ONSET ATRIAL FIBRILLATION AFTER 10 YEARS OF FOLLOW UP IN CARDIOEMBOLIC STROKE

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.4 LIPIDS**

- P 211 LIPID PROFILE IN ADULT HEALTHY POPULATION FROM MADEIRA ISLAND  
 P 212 NEW VALUES OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ACUTE CORONARY SYNDROME-ARE WE FAR FROM THEM?  
 P 213 LIPOPROTEIN(A) AND MAJOR CARDIOVASCULAR EVENTS: 15-YEAR FOLLOW-UP IN A SOUTHERN EUROPEAN POPULATION  
 P 215 SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME - CAN WE ACHIEVE DYSLIPIDEMIA GUIDELINE TARGETS?

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.7 DIABETES AND THE HEART**

- P 68 DIABETES AS A FACTOR FOR INCREASED NT-PROBNP LEVELS IN PATIENTS WITHOUT HEART FAILURE

P 138 POLYMORPHISMS OF ACE GENE ARE ASSOCIATED WITH THE ONSET OF METABOLIC SYNDROME IN A PORTUGUESE POPULATION

P 214 PREVALENCE AND PREDICTORS OF GLUCOSE METABOLISM DISORDERS AFTER ACUTE CORONARY SYNDROME

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.14 RISK FACTORS AND PREVENTION - OTHER**

P 210 HIGH DENSITY LIPOPROTEIN CHOLESTEROL AND ALCOHOL CONSUMPTION: ARE THEY RELATED?

## **J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.2 CARDIOVASCULAR REHABILITATION**

P 282 THE IMPACT OF THE CARDIAC REHABILITATION PROGRAM IN PATIENTS WITH MID-RANGE HEART FAILURE (40-50%) IN IMPROVING CARDIO RESPIRATORY PREDICTORS

P 283 EXERCISE-BASED CARDIAC REHABILITATION: A REAL-WORLD PROGRAM EVALUATION

P 284 PREDICTORS OF PHYSICAL INACTIVITY 1 YEAR AFTER A CARDIAC REHABILITATION PROGRAM

P 285 CARDIAC REHABILITATION PROGRAM - REAL LIFE RESULTS

P 286 PREDICTORS OF QUALITY OF LIFE AFTER CARDIAC REHABILITATION

P 287 IMPACT OF CARDIAC REHABILITATION ON PHYSICAL FITNESS AND HEALTH STATUS

P 312 CARDIAC REHABILITATION IN STEMI: AN ASSESSMENT OF FUNCTIONAL CAPACITY IMPROVEMENT

## **J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.3 SPORTS CARDIOLOGY**

P 307 ELECTROCARDIOGRAPHIC CRITERIA TO DETECT CARDIAC ABNORMALITIES IN ATHLETES - A PORTUGUESE STUDY

## **K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.6 CARDIO-ONCOLOGY**

P 47 IMPACT OF PREVIOUS NEOPLASIA IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

P 354 EARLY PREDICTORS OF CARDIOTOXICITY IN PATIENTS UNDER ANTHRACYCLINES

P 355 PREDICTORS OF CARDIOTOXICITY AFTER CHEMOTHERAPY WITH TRANSTUZUMAB

P 358 CAN WE ACCESS CARDIOVASCULAR RISK IN RADIOTHERAPY PATIENTS?

## **K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.7 PREGNANCY AND CARDIOVASCULAR DISEASE**

P 127 PREGNANCY OUTCOMES IN WOMEN WITH MECHANICAL HEART VALVES: TWENTY-YEAR 'S EXPERIENCE OF A TERTIARY CENTRE

## **K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.14 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS - OTHER**

P 40 MINOCA PATIENTS PRESENTING WITH ST SEGMENT ELEVATION: LOOK BEYOND THE CATCHY NAME

P 42 KASH SCORE BEYOND MYOCARDIAL INFARCTION: A NEW RISK STRATIFICATION TOOL FOR MYOCARDIAL INJURY?

P 52 THE IMPACT OF OBESITY ON CARDIAC FUNCTION AND MORPHOLOGY IN AORTIC STENOSIS

P 271 EFEITO DA ANGIOPLASTIA PULMONAR DE BALÃO NA FUNÇÃO RESPIRATÓRIA EM DOENTES COM HIPERTENSÃO PULMONAR

P 273 AVALIAÇÃO DA RESPOSTA AO ESFORÇO NA HIPERTENSÃO PULMONAR TROMBOEMBÓLICA CRÔNICA APÓS-TRATAMENTO

- P 308 ESTUDO ELETROFISIOLÓGICO NA ESTRATIFICAÇÃO DE RISCO DE DOENTES COM SÍNDROME DE BRUGADA  
 P 359 VERY FRAGILE PATIENTS WITH ATRIAL FIBRILLATION: TO ANTICOAGULATE OR NOT IS THE QUESTION!

**L. CARDIOVASCULAR PHARMACOLOGY -> 31. PHARMACOLOGY AND PHARMACOTHERAPY  
 -> 31.1 CARDIOVASCULAR PHARMACOTHERAPY**

- P 356 STATINS FOR VENOUS THROMBOEMBOLISM PREVENTION: OLD DOG, NEW TRICKS

**L. CARDIOVASCULAR PHARMACOLOGY -> 31. PHARMACOLOGY AND PHARMACOTHERAPY  
 -> 31.5 PHARMACOLOGY AND PHARMACOTHERAPY - OTHER**

- P 357 THROMBIN GENERATION TEST IS SUPERIOR TO CONVENTIONAL TESTS TO MONITOR DIRECT ORAL ANTICOAGULANTS

**M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.1 ACUTE NURSING CARE**

- P 331 MULTICENTER RANDOMIZED CONTROLLED TRIAL: ERIC-HF PROTOCOL RESULTS

**M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.3 CARDIOVASCULAR NURSING - OTHER**

- P 330 ADESÃO AO REGIME MEDICAMENTOSO - UMA REALIDADE  
 P 332 THE THERAPEUTIC REGIMEN MANAGEMENT IN THE CARDIAC REHABILITATION PROGRAM  
 P 333 ENFERMAGEM DE REABILITAÇÃO NA CARDIOLOGIA - UMA REALIDADE  
 P 334 CARACTERIZAÇÃO DOS DOENTES SUBMETIDOS A CIRURGIA NUMA UNIDADE DE SAÚDE HOSPITALAR E CONSEQUENTES NECESSIDADES DE CUIDADOS DE ENFERMAGEM - UM ESTUDO RETROSPECTIVO  
 P 335 IMPACTO DA INSUFICIÊNCIA CARDÍACA NA SEXUALIDADE

**N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.1 PUBLIC HEALTH**

- P 313 INEQUALITIES AFTER STEMI IN NHS SERVICES: IS THERE REALLY A POSTCODE LOTTERY?  
 P 315 SGLT2 INHIBITORS IN A POST-ACUTE CORONARY SYNDROME POPULATION

**N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.3 HEALTH ECONOMICS**

- P 93 SYNCOPE IN A LARGE PORTUGUESE NATIONWIDE INPATIENT SAMPLE - EPIDEMIOLOGY AND IN-HOSPITAL COSTS

**N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 35. RESEARCH METHODOLOGY -> 35.2 RESEARCH METHODOLOGY: BIG DATA ANALYSIS**

- P 314 PATHWAYS: ASSESSMENT OF DISTANCE TO PCI AND MORTALITY IN STEMI WITH PROCESS MINING TOOLS

**O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.3 BASIC SCIENCE - CARDIAC DISEASES**

- CO 9 PLASMA LIPIDOMIC PROFILING IN HEART FAILURE WITH PRESERVED EJECTION FRACTION  
 CO 10 CHANGES ON DIASTOLIC FUNCTION AFTER PHYSICAL EXERCISE IN A DOXORUBICIN MODEL - PRELIMINARY RESULTS FROM TRACKING3C TRANSLATIONAL PROJECT

- CO 36 HAS THE TIME COME TO INTEGRATE GENETIC RISK SCORES INTO CLINICAL PRACTICE?
- CO 38 ROLE OF UROCORTIN-2 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
- CO 41 THYROID HORMONE AS A THERAPY FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION IN A RAT MODEL

## **O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.4 BASIC SCIENCE - VASCULAR BIOLOGY AND PHYSIOLOGY**

- CO 7  $\beta$ -3 ADRENOCEPTORS: A THERAPEUTIC TARGET FOR PULMONARY ARTERIAL HYPERTENSION

## **O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.6 BASIC SCIENCE - OTHER**

- CO 11 CHEMOREFLEX OVEREXCITATION, BAROREFLEX IMPAIRMENT, SYMPATHOVAGAL IMBALANCE AND MULTIPLE ORGAN DYSFUNCTION INDUCED BY LIPOPOLYSACCHARIDE-EXPOSED RATS

## **P. OTHER -> 37. MISCELLANEA**

- P 270 RIGHT CATHETERIZATION PARAMETERS PREDICTION IN THE FIRST YEAR AFTER HEART TRANSPLANT USING BNP
- P 316 THE EPIDEMIOLOGY OF OUT OF HOSPITAL CARDIAC ARREST IN PORTUGAL IN 2018
- P 317 O SCORE DE CHA2DS2-VASC COMO PREDITOR NA REABILITAÇÃO CARDÍACA DE DOENTES CORONÁRIOS